{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:50:00Z","timestamp":1793346600727,"version":"4.5.0"},"reference-count":80,"publisher":"Becaris Publishing Limited","issue":"5","funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To conduct indirect treatment comparisons between risdiplam and other approved treatments for spinal muscular atrophy (SMA).\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            Individual patient data from risdiplam trials were compared with aggregated data from published studies of nusinersen and onasemnogene abeparvovec, accounting for heterogeneity across studies.\n            <jats:bold>Results:<\/jats:bold>\n            In Type 1 SMA, studies of risdiplam and nusinersen included similar populations. Indirect comparison results found improved survival and motor function with risdiplam versus nusinersen. Comparison with onasemnogene abeparvovec in Type 1 SMA and with nusinersen in Types 2\/3 SMA was challenging due to substantial differences in study populations; no concrete conclusions could be drawn from the indirect comparison analyses.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Indirect comparisons support risdiplam as a superior alternative to nusinersen in Type 1 SMA.\n          <\/jats:p>","DOI":"10.2217\/cer-2021-0216","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:03:44Z","timestamp":1642514624000},"page":"347-370","source":"Crossref","is-referenced-by-count":42,"title":["How does risdiplam compare with other treatments for Types 1\u20133 spinal muscular atrophy: a systematic literature review and indirect treatment comparison"],"prefix":"10.57264","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0034-0182","authenticated-orcid":false,"given":"Valerie Aponte","family":"Ribero","sequence":"first","affiliation":[{"name":"Global Access, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-8288","authenticated-orcid":false,"given":"Monica","family":"Daigl","sequence":"additional","affiliation":[{"name":"Global Access, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Mart\u00ed","sequence":"additional","affiliation":[{"name":"Global Access, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Gorni","sequence":"additional","affiliation":[{"name":"PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-0262","authenticated-orcid":false,"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-8046","authenticated-orcid":false,"given":"David Alexander","family":"Scott","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadi","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Bridge Medical Consulting Ltd., Richmond, London, TW9 2SS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-1567","authenticated-orcid":false,"given":"Keith R","family":"Abrams","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy \u2013 a literature review","volume":"12","author":"Verhaart IEC","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy \u2013 a literature review. Orphanet J. Rare Dis. 12(1), 124 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'amico A","year":"2011","unstructured":"D'amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J. Rare Dis. 6, 71 (2011).","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre S","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1), 155\u2013165 (1995).","journal-title":"Cell"},{"issue":"1","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1086\/513913","article-title":"When is a deletion not a deletion? When it is converted","volume":"61","author":"Burghes AH","year":"1997","unstructured":"Burghes AH. When is a deletion not a deletion? When it is converted. Am. J. Hum. Genet. 61(1), 9\u201315 (1997).","journal-title":"Am. J. Hum. Genet."},{"issue":"11","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson CL","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96(11), 6307\u20136311 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/GIM.0b013e3181c5e713","article-title":"Perspectives and diagnostic considerations in spinal muscular atrophy","volume":"12","author":"Prior TW","year":"2010","unstructured":"Prior TW. Perspectives and diagnostic considerations in spinal muscular atrophy. Genet. Med. 12, 145\u2013152 (2010).","journal-title":"Genet. Med."},{"issue":"3","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh RN","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochim. Biophys. Acta Gene Regul. Mech. 1860(3), 299\u2013315 (2017).","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"issue":"5","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting. (26\u201328 June 1992, Bonn, Germany)","volume":"2","author":"Munsat TL","year":"1992","unstructured":"Munsat TL, Davies KE. International SMA consortium meeting. (26\u201328 June 1992, Bonn, Germany). Neuromusc. Disord. 2(5\u20136), 423\u2013428 (1992).","journal-title":"Neuromusc. Disord."},{"issue":"2","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1090-3798(99)80012-9","article-title":"Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype","volume":"3","author":"Dubowitz V","year":"1999","unstructured":"Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur. J. Paediatr. Neurol. 3(2), 49\u201351 (1999).","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel RS","year":"2014","unstructured":"Finkel RS, Mcdermott MP, Kaufmann P Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83(9), 810\u2013817 (2014).","journal-title":"Neurology"},{"issue":"5","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri E","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 11(5), 443\u2013452 (2012).","journal-title":"Lancet Neurol."},{"issue":"6","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archneurol.2010.373","article-title":"Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year","volume":"68","author":"Kaufmann P","year":"2011","unstructured":"Kaufmann P, Mcdermott MP, Darras BT Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch. Neurol. 68(6), 779\u2013786 (2011).","journal-title":"Arch. Neurol."},{"issue":"1","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar MA","year":"2013","unstructured":"Farrar MA, Vucic S, Johnston HM, Du Sart D, Kiernan MC. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J. Pediatrics 162(1), 155\u2013159 (2013).","journal-title":"J. Pediatrics"},{"issue":"1","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/fnl.13.58","article-title":"Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond","volume":"9","author":"Monani UR","year":"2014","unstructured":"Monani UR, De Vivo DC. Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond. Future Neurol. 9(1), 49\u201365 (2014).","journal-title":"Future Neurol."},{"issue":"15","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni H","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J. Med. Chem. 61(15), 6501\u20136517 (2018).","journal-title":"J. Med. Chem."},{"key":"e_1_3_7_18_2","unstructured":"EVRYSDI(R) Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf (September)."},{"key":"e_1_3_7_19_2","unstructured":"Evrysdi (risdiplam) EMA prescribing information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evrysdi-epar-product-information_en.pdf (May)."},{"issue":"10","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 spinal muscular atrophy","volume":"384","author":"Baranello G","year":"2021","unstructured":"Baranello G, Darras BT, Day JW Risdiplam in Type 1 spinal muscular atrophy. N. Engl. J. Med. 384(10), 915\u2013923 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with Type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras BT","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M Risdiplam-treated infants with Type 1 spinal muscular atrophy versus historical controls. N. Engl. J. Med. 385(5), 427\u2013435 (2021).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_22_2","article-title":"Safety and efficacy of once-daily risdiplam in Type 2 and non-ambulant Type 3 spinal muscular atrophy: a Phase III, double-blind, randomised, placebo-controlled trial","author":"Mercuri E","year":"2021","unstructured":"Mercuri E, Deconinck N, Mazzone E Safety and efficacy of once-daily risdiplam in Type 2 and non-ambulant Type 3 spinal muscular atrophy: a Phase III, double-blind, randomised, placebo-controlled trial. Lancet Neurol., (2021).","journal-title":"Lancet Neurol."},{"key":"e_1_3_7_23_2","unstructured":"SPINRAZA \u00ae (nusinersen) EMA prescribing information. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004312\/WC500229704.pdf (November)."},{"key":"e_1_3_7_24_2","unstructured":"SPINRAZA \u00ae (nusinersen) US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf (November)."},{"key":"e_1_3_7_25_2","unstructured":"NCT02193074: a study to assess the efficacy and safety of ISIS-SMNRx in infants with spinal muscular atrophy (ENDEAR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193074 (July)."},{"key":"e_1_3_7_26_2","unstructured":"NCT02292537: a study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later-onset spinal muscular atrophy (SMA) (CHERISH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02292537 (Accessed December 2020)."},{"key":"e_1_3_7_27_2","unstructured":"ZOLGENSMA \u00ae (onasemnogene abeparvovec-xioi) US prescribing information. https:\/\/www.fda.gov\/media\/126109\/download (November)."},{"key":"e_1_3_7_28_2","unstructured":"ZOLGENSMA \u00ae (onasemnogene abeparvovec-xioi). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma (November)."},{"key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell J","year":"2017","unstructured":"Mendell J. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell JR","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 78(7), 834\u2013841 (2021).","journal-title":"JAMA Neurol."},{"issue":"4","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, Phase III trial","volume":"20","author":"Day JW","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, Phase III trial. Lancet Neurol. 20(4), 284\u2013293 (2021).","journal-title":"Lancet Neurol."},{"key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1017\/cjn.2019.160","article-title":"P.060 Time to treatment effect in spinal muscular atrophy Type 1 (SMA1): an indirect comparison of treatments","volume":"46","author":"Finkel RS","year":"2019","unstructured":"Finkel RS, Dabbous O, Arjunji R P.060 Time to treatment effect in spinal muscular atrophy Type 1 (SMA1): an indirect comparison of treatments. Can. J. Neurologic. Sci. 46, S30 (2019).","journal-title":"Can. J. Neurologic. Sci."},{"issue":"5","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy Type 1","volume":"36","author":"Dabbous O","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy Type 1. Adv. Ther. 36(5), 1164\u20131176 (2019).","journal-title":"Adv. Ther."},{"key":"e_1_3_7_34_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2020.08.1845","article-title":"PR109 a cautionary tale for indirect treatment comparisons: an example from infantile-onset spinal muscular atrophy","volume":"23","author":"Liao S","year":"2020","unstructured":"Liao S, Bohn J, De Moor C, Xaplanteris X, Farwell W, Padaris A. PR109 a cautionary tale for indirect treatment comparisons: an example from infantile-onset spinal muscular atrophy. Value Health 23, (2020).","journal-title":"Value Health"},{"key":"e_1_3_7_35_2","article-title":"Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy Type 1","author":"Bischof M","year":"2021","unstructured":"Bischof M, Lorenzi M, Lee J, Druyts E, Balijepalli C, Dabbous O. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy Type 1. Curr. Med. Res. Opin. doi:10.1080\/03007995.2021.1947216 (2021) (Epub ahead of print).","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"e_1_3_7_36_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher HC","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50(6), 683\u2013691 (1997).","journal-title":"J. Clin. Epidemiol."},{"key":"e_1_3_7_37_2","unstructured":"Phillippo DM Ades AE Dias S Palmer S Abrams KR Welton NJ. NICE DSU technical document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (2016)."},{"key":"e_1_3_7_38_2","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2247","article-title":"Prognostic factors and treatment-effect modifiers in spinal muscular atrophy","author":"Baranello G","year":"2021","unstructured":"Baranello G, Gorni K, Daigl M Prognostic factors and treatment-effect modifiers in spinal muscular atrophy. Clin. Pharmacol. Therapeut., doi:https:\/\/doi.org\/10.1002\/cpt.2247 (2021) (Epub ahead of print).","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman AM","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromusc. Disord. 20, 155\u2013161 (2010).","journal-title":"Neuromusc. Disord."},{"issue":"2","key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA Type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann A","year":"2018","unstructured":"Pechmann A, Langer T, Schorling D Evaluation of children with SMA Type 1 under treatment with nusinersen within the expanded access program in Germany. J. Neuromuscul. Dis. 5(2), 135\u2013143 (2018).","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy M","year":"2021","unstructured":"Annoussamy M, Seferian A, Daron A Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann. Clin. Transl. Neurol. 8(2), 359\u2013373 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"e_1_3_7_42_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of Type I spinal muscular atrophy: a critical review","volume":"15","author":"Mercuri E","year":"2020","unstructured":"Mercuri E, Lucibello S, Perulli M Longitudinal natural history of Type I spinal muscular atrophy: a critical review. Orphanet J. Rare Dis. 15(1), 84 (2020).","journal-title":"Orphanet J. Rare Dis."},{"issue":"11","key":"e_1_3_7_43_2","first-page":"113","article-title":"Proximal spinal muscular atrophy: current orthopedic perspective","volume":"6","author":"Haaker G","year":"2013","unstructured":"Haaker G, Fujak A. Proximal spinal muscular atrophy: current orthopedic perspective. App. Clin. Genet. 6(11), 113\u2013120 (2013).","journal-title":"App. Clin. Genet."},{"key":"e_1_3_7_44_2","unstructured":"NCT02913482: a study to investigate the safety tolerability pharmacokinetics pharmacodynamics and efficacy of RO7034067 in infants with Type 1 spinal muscular atrophy (FIREFISH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02913482 (July)."},{"key":"e_1_3_7_45_2","unstructured":"NCT03306277: gene replacement therapy clinical trial for patients with spinal muscular atrophy Type 1 (STR1VE-US). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03306277?term=AVXS-101&rank=2 (July)."},{"key":"e_1_3_7_46_2","unstructured":"NCT01839656: a study to assess the safety and pharmacokinetics of ISIS SMNRx in infants with spinal muscular atrophy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01839656"},{"key":"e_1_3_7_47_2","unstructured":"NCT02122952: gene transfer clinical trial for spinal muscular atrophy Type 1. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02122952 (July)."},{"key":"e_1_3_7_48_2","unstructured":"NCT03837184: single-dose gene replacement therapy using for patients with spinal muscular atrophy Type 1 with one or two SMN2 copies (STR1VE-AP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03837184?term=NCT03837184&draw=2&rank=1 (Accessed 2020)."},{"key":"e_1_3_7_49_2","unstructured":"NCT03461289: single-dose gene replacement therapy clinical trial for patients with spinal muscular atrophy Type 1 (STRIVE-EU). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03461289?term=NCT03461289&draw=2&rank=1 (Accessed 2020)."},{"key":"e_1_3_7_50_2","unstructured":"NCT02268552: an open-label study of LMI070 in Type 1 spinal muscular atrophy (SMA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268552"},{"key":"e_1_3_7_51_2","unstructured":"NCT02908685: a study to investigate the safety tolerability pharmacokinetics pharmacodynamics and efficacy of RO7034067 in Type 2 and 3 spinal muscular atrophy participants (SUNFISH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02908685 (July)."},{"issue":"9","key":"e_1_3_7_52_2","first-page":"920","article-title":"Results of a Phase 2 study of ISIS-SMNRx in children with spinal muscular atrophy","volume":"24","author":"Darras B","year":"2014","unstructured":"Darras B, Chiriboga C, Swoboda K Results of a Phase 2 study of ISIS-SMNRx in children with spinal muscular atrophy. Neuromusc. Disord. 24(9\u201310), 920 (2014).","journal-title":"Neuromusc. Disord."},{"issue":"10","key":"e_1_3_7_53_2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a Phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga CA","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT Results from a Phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86(10), 890\u2013897 (2016).","journal-title":"Neurology"},{"key":"e_1_3_7_54_2","unstructured":"NCT01703988: an open-label safety tolerability and dose-range finding study of multiple doses of ISIS SMNRx in patient with spinal muscular atrophy (SMNRx - CS2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01703988"},{"key":"e_1_3_7_55_2","unstructured":"NCT02052791: an open-label safety and tolerability study of nusinersen (ISIS 396443) in participants with spinal muscular atrophy (SMA) who previously participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (Accessed August 2020)."},{"key":"e_1_3_7_56_2","unstructured":"NCT01302600: safety and efficacy of olesoxime (TRO19622) in 3\u201325 years SMA patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302600 (Accessed June 2020)."},{"key":"e_1_3_7_57_2","unstructured":"NCT03032172: a study of RO7034067 in adult and pediatric participants with spinal muscular atrophy (JEWELFISH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03032172 (July)."},{"key":"e_1_3_7_58_2","unstructured":"NCT03921528: an active treatment study of SRK-015 in patients with Type 2 or Type 3 spinal muscular atrophy (TOPAZ). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03921528 (Accessed September 2020)."},{"key":"e_1_3_7_59_2","unstructured":"NCT04089566: study of nusinersen (BIIB058) in participants with spinal muscular atrophy (DEVOTE). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04089566"},{"key":"e_1_3_7_60_2","unstructured":"NCT02462759: a study to assess the safety and tolerability of nusinersen (ISIS 396443) in participants with spinal muscular atrophy (SMA). (EMBRACE). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02462759 (Accessed July 2021)."},{"key":"e_1_3_7_61_2","unstructured":"NCT02594124: a study for participants with spinal muscular atrophy (SMA) who previously participated in nusinersen (ISIS 396443) investigational studies. (SHINE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02594124 (July)."},{"key":"e_1_3_7_62_2","unstructured":"NCT04042025: long-term follow-up study of patients receiving onasemnogene abeparvovec-xioi. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04042025 (Accessed July 2021)."},{"issue":"1","key":"e_1_3_7_63_2","first-page":"241","article-title":"CK-2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy","volume":"17","author":"Rudnicki S","year":"2016","unstructured":"Rudnicki S, Andrews J, Malik F, Wolff A, Day. CK-2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotroph. Lateral Scler. Frontotemporal Degener. 17(1), 241 (2016).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"e_1_3_7_64_2","unstructured":"NCT02628743: a study to evaluate long term safety tolerability and effectiveness of olesoxime in patients with spinal muscular atrophy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02628743 (November)."},{"key":"e_1_3_7_65_2","unstructured":"NCT03381729: study of intrathecal administration of AVXS-101 for spinal muscular atrophy (STRONG). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03381729?term=strong&cond=Spinal+Muscular+Atrophy&rank=1"},{"key":"e_1_3_7_66_2","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/j.nmd.2019.06.511","article-title":"P.349Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy Type 1 (SMA1): pivotal Phase III study (STR1VE) update","volume":"29","author":"Day J","year":"2019","unstructured":"Day J, Chiriboga C, Crawford T P.349Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy Type 1 (SMA1): pivotal Phase III study (STR1VE) update. Neuromusc. Disord. 29, S183 (2019).","journal-title":"Neuromusc. Disord."},{"issue":"18","key":"e_1_3_7_67_2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel RS","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377(18), 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_68_2","unstructured":"European Medicines Agency CFMPFHU Committee for Advanced Therapies. Assessment report: zolgensma (2020). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zolgensma-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_7_69_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri E","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625\u2013635 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_7_70_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch JE","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28(10), 935\u2013945 (2010).","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"e_1_3_7_71_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"6","key":"e_1_3_7_72_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"key":"e_1_3_7_73_2","doi-asserted-by":"crossref","first-page":"S843","DOI":"10.1016\/j.jval.2019.09.2344","article-title":"PRO12: how does risdiplam compare in infantile-onset spinal muscular atrophy (SMA)? Preliminary indirect treatment comparisons based on FIREFISH Part 1 data","volume":"22","author":"Daigl M","year":"2019","unstructured":"Daigl M, Kotzeva A, Gorni K PRO12: how does risdiplam compare in infantile-onset spinal muscular atrophy (SMA)? Preliminary indirect treatment comparisons based on FIREFISH Part 1 data. Value Health 22, S843 (2019).","journal-title":"Value Health"},{"issue":"3","key":"e_1_3_7_74_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo DM","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE Multilevel network meta-regression for population-adjusted treatment comparisons. J. R. Stat. Soc. Ser. A Stat. Soc. 183(3), 1189\u20131210 (2020).","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"issue":"7644","key":"e_1_3_7_75_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood L","year":"2008","unstructured":"Wood L, Egger M, Gluud LL Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336(7644), 601\u2013605 (2008).","journal-title":"BMJ"},{"issue":"2","key":"e_1_3_7_76_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri E","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromusc. Disord. 28(2), 103\u2013115 (2018).","journal-title":"Neuromusc. Disord."},{"issue":"3","key":"e_1_3_7_77_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel RS","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromusc. Disord. 28(3), 197\u2013207 (2018).","journal-title":"Neuromusc. Disord."},{"issue":"13","key":"e_1_3_7_78_2","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1212\/WNL.0000000000008166","article-title":"Long-term progression in type II spinal muscular atrophy: a retrospective observational study","volume":"93","author":"Mercuri E","year":"2019","unstructured":"Mercuri E, Lucibello S, Pera MC Long-term progression in type II spinal muscular atrophy: a retrospective observational study. Neurology 93(13), e1241\u2013e1247 (2019).","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_7_79_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mus.20018","article-title":"Motor function-muscle strength relationship in spinal muscular atrophy","volume":"29","author":"Merlini L","year":"2004","unstructured":"Merlini L, Bertini E, Minetti C Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve 29(4), 548\u2013552 (2004).","journal-title":"Muscle Nerve"},{"key":"e_1_3_7_80_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1741-7015-7-14","article-title":"Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy","volume":"7","author":"Millino C","year":"2009","unstructured":"Millino C, Fanin M, Vettori A Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. BMC Med. 7, 14 (2009).","journal-title":"BMC Med."},{"issue":"10","key":"e_1_3_7_81_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40263-017-0462-8","article-title":"Can matching-adjusted indirect comparison methods mitigate placebo response differences among patient populations in adjunctive trials of brivaracetam and levetiracetam?","volume":"31","author":"Swallow E","year":"2017","unstructured":"Swallow E, Fang A, Signorovitch JE, Plumb J, Borghs S. Can matching-adjusted indirect comparison methods mitigate placebo response differences among patient populations in adjunctive trials of brivaracetam and levetiracetam? CNS Drugs 31(10), 899\u2013910 (2017).","journal-title":"CNS Drugs"},{"issue":"10","key":"e_1_3_7_82_2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40263-019-00672-w","article-title":"Using matching-adjusted indirect comparisons and network meta-analyses to compare efficacy of brexanolone injection with selective serotonin reuptake inhibitors for treating postpartum depression","volume":"33","author":"Cooper M","year":"2019","unstructured":"Cooper M, Kilvert H, Hodgkins P, Roskell N, Eldar-Lissai A. Using matching-adjusted indirect comparisons and network meta-analyses to compare efficacy of brexanolone injection with selective serotonin reuptake inhibitors for treating postpartum depression. CNS Drugs 33(10), 1039\u20131052 (2019).","journal-title":"CNS Drugs"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2021-0216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:13:10Z","timestamp":1679231590000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.2217\/cer-2021-0216"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0216","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}